ClinicalTrials.gg

Program

evenamide hydrochloride

Also written as “Evenamide”, “Evenamide 15 mg bid” and “NW-3509a”.

Its studies are mostly in Schizophrenia · Schizophrenia, Treatment-Resistant, led by Newron Pharmaceuticals SPA.

Furthest: phase 3, since Sep 18, 20255 company-led studies, 1 open or runningNext primary completion: Mar 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Newron Pharmaceuticals SPA51 open or runningphase 3since Sep 18, 2025Aug 21, 2013Mar 31, 2027phase 3 · NCT07184619

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 21, 2013First study: phase 1 study in SchizophreniaFirst studyNCT01955564 · 54 enrolled · United States
  2. Nov 20, 2015Phase 2 study in Chronic SchizophreniaNCT02624167 · 90 enrolled · United States, India
  3. Jan 29, 2018Phase 1 study in HealthyNCT03446274 · 6 enrolled · United Kingdom
  4. Jun 19, 2020Phase 2 study in SchizophreniaNCT04461119 · 138 enrolled · United States, India
  5. Sep 18, 2025Phase 3 study in Schizophrenia, Treatment-ResistantNCT07184619 · 400 planned · United States, Argentina, Colombia and more

Ahead

  1. Mar 31, 2027Primary completion: phase 3 study in Schizophrenia, Treatment-ResistantNCT07184619

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07184619Schizophrenia, Treatment-Resistant · United States, Argentina, Colombia and more3RecruitingMar 31, 2027400
NCT04461119Schizophrenia · United States, India2CompletedFeb 20, 2021138
NCT03446274Healthy · United Kingdom1UNKNOWNApr 23, 20186
NCT02624167Chronic Schizophrenia · United States, India2CompletedDec 201690
NCT01955564Schizophrenia · United States1CompletedSep 201454

How it is read

Names in the registry

  • “Evenamide”, 2 entries
  • “Evenamide 15 mg bid”, 1 entry
  • “NW-3509a”, 1 entry
  • “NW-3509A”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.